PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis

p53 deficiency confers resistance to doxo (doxorubicin), a clinically active and widely used antitumour anthracycline antibiotic. The purpose of the present study was to investigate the reversal mechanism of doxo resistance by the potent PARP [poly(ADP-ribose) polymerase] inhibitor ANI (4-amino-1,8-...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Muñoz-Gámez, José Antonio, Martín-Oliva, David, Aguilar-Quesada, Rocío, Cañuelo, Ana, Nuñez, M. Isabel, Valenzuela, M. Teresa, Ruiz de Almodóvar, J. M., de Murcia∥, Gilbert, Oliver, F. Javier
Format: Artigo
Langue:Inglês
Publié: Portland Press Ltd. 2005
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC1134773/
https://ncbi.nlm.nih.gov/pubmed/15456408
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1042/BJ20040776
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires